These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 20709365)

  • 1. The effect of escitalopram on platelet activity.
    Canan F; Ataoglu A
    Thromb Res; 2011 Jan; 127(1):57. PubMed ID: 20709365
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline.
    Flöck A; Zobel A; Bauriedel G; Tuleta I; Hammerstingl C; Höfels S; Schuhmacher A; Maier W; Nickenig G; Skowasch D
    Thromb Res; 2010 Aug; 126(2):e83-7. PubMed ID: 20553948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans.
    Atar D; Malinin A; Takserman A; Pokov A; van Zyl L; Tanguay JF; Lesperance F; Serebruany V
    J Clin Psychopharmacol; 2006 Apr; 26(2):172-7. PubMed ID: 16633147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant treatment increases quality of life in patients with chronic renal failure.
    Kalender B; Ozdemir AC; Yalug I; Dervisoglu E
    Ren Fail; 2007; 29(7):817-22. PubMed ID: 17994449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of escitalopram on sleep problems in depressed patients.
    Lader M; Andersen HF; Baekdal T
    Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
    Llorca PM; Azorin JM; Despiegel N; Verpillat P
    Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Change in platelet aggregation and ATP secretion: is there an early prediction of antidepressive therapy? (preliminary report)].
    Peter L; Schweitzer K; Kovacs G
    Neuropsychopharmacol Hung; 2011 Jun; 13(2):87-91. PubMed ID: 21677322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The onset of effect for escitalopram and its relevance for the clinical management of depression.
    Wade A; Friis Andersen H
    Curr Med Res Opin; 2006 Nov; 22(11):2101-10. PubMed ID: 17076970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escitalopram for the treatment of major depression and anxiety disorders.
    Höschl C; Svestka J
    Expert Rev Neurother; 2008 Apr; 8(4):537-52. PubMed ID: 18416657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superiority of escitalopram to paroxetine in the treatment of depression.
    Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
    Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antidepressants in the treatment of alcoholism].
    Sivolap IuP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):32-5. PubMed ID: 22951795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escitalopram H Lundbeck.
    McRae AL
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1225-9. PubMed ID: 12211420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Activity of platelet serotonin receptors of patients with endogenous depression before and after treatment with antidepressive agents].
    Katasonov AB; Beliaev BS; Brusov OS; Zlobina GP; Faktor MI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(12):75-8. PubMed ID: 2633575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram in seasonal affective disorder: results of an open trial.
    Pjrek E; Winkler D; Stastny J; Praschak-Rieder N; Willeit M; Kasper S
    Pharmacopsychiatry; 2007 Jan; 40(1):20-4. PubMed ID: 17327956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression.
    Bech P; Tanghøj P; Andersen HF; Overø K
    Psychopharmacology (Berl); 2002 Aug; 163(1):20-5. PubMed ID: 12185396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.
    Leuchter AF; Husain MM; Cook IA; Trivedi MH; Wisniewski SR; Gilmer WS; Luther JF; Fava M; Rush AJ
    Psychol Med; 2010 Feb; 40(2):239-51. PubMed ID: 19493369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
    Rabinowitz I; Baruch Y; Barak Y
    Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.